Infection with the human immunodeficiency virus (HIV) leads to progressive destruction and weakening of the body's immune system. Patients with advanced HIV disease are vulnerable to various diseases, called opportunistic infections (OIs), which most people with normal immune systems are protected against. One of these OIs, a fungal disease called cryptococcosis, causes meningitis (an inflammation of the membrane surrounding the brain) and pneumonia and is lethal when untreated. This study looked at two medications, itraconazole and fluconazole, which could be taken by patients with advanced HIV disease, to prevent this fungal infection from ever occurring. This study found that both were effective drugs for preventing cryptococcal disease. However, these drugs were not found to be effective in decreasing the overall death rates from HIV. More studies of these medications are needed to further evaluate their cost-effectiveness and benefits in decreasing death rates in groups of patients with HIV.
Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV
21 January 2009
This record should be cited as:
Chang LW, Phipps WT, Kennedy GE, Rutherford G. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD004773. DOI: 10.1002/14651858.CD004773.pub2
Assessed as up to date:
23 May 2005
More like this
- Management of toxoplasmic encephalitis in HIV-infected adults (with an emphasis on resource-poor settings)
- Treatment of acute cryptococcal meningitis in HIV infected adults, with an emphasis on resource-limited settings
- The impact of tuberculosis preventive therapy on tuberculosis and death in HIV-infected children
- Interventions for the prevention and management of oral thrush associated with HIV infection in adults and children
- This review examines strategies to enable the continued use of the antibiotic cotrimoxazole in patients with HIV/AIDS to treat or prevent opportunistic infections in patients who previously experienced hypersensitivity to this drug.